haloperidol has been researched along with Acute Confusional Senile Dementia in 57 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The use of baclofen, a structural analog of gamma-aminobutyric acid (GABA), is described in the treatment of a patient with tardive dystonia." | 7.67 | Baclofen treatment in a patient with tardive dystonia. ( Allen, A; Lux, WE; Rosse, RB, 1986) |
| " Using an optimizing dosage regime, the outcome variables studied were aggression frequency and the number and nature of emergent side effects." | 6.67 | Aggression in the demented patient: a double-blind study of loxapine versus haloperidol. ( Ancill, RJ; Carlyle, W; Sheldon, L, 1993) |
| "The goal of this study was to compare the efficacy and safety of olanzapine versus haloperidol in the treatment of agitation and aggression in patients with dementia." | 5.12 | Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial. ( Lousberg, R; Verhey, FR; Verkaaik, M, 2006) |
| "For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation." | 5.08 | A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. ( Bell, K; Cooper, TB; Devanand, DP; Marder, K; Mayeux, R; Michaels, KS; Pelton, GH; Sackeim, HA; Sullivan, MA, 1998) |
| "Fifty-nine elderly residents of long-term care facilities who had DSM-III diagnoses of dementia were studied in an 8-week randomized, double-blind comparison trial of haloperidol, oxazepam, and diphenhydramine to test the efficacy of these agents in the treatment of clinically significant behavioral disturbances in patients with dementia." | 5.06 | Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. ( Coccaro, EF; Duvvi, K; Giordani, B; Kramer, E; Nora, R; Patel, BM; Rice, CM; Thorne, A; Torres, J; Zemishlany, Z, 1990) |
| "3-3 mg/kg) did not induce EPS signs by itself; however, it significantly potentiated bradykinesia induction with a low dose of haloperidol (0." | 3.81 | Interaction between anti-Alzheimer and antipsychotic drugs in modulating extrapyramidal motor disorders in mice. ( Fujiwara, M; Mizuguchi, Y; Morimoto, T; Ohno, Y; Shimizu, S; Sobue, A, 2015) |
| "The use of baclofen, a structural analog of gamma-aminobutyric acid (GABA), is described in the treatment of a patient with tardive dystonia." | 3.67 | Baclofen treatment in a patient with tardive dystonia. ( Allen, A; Lux, WE; Rosse, RB, 1986) |
| "Haloperidol open treatment was efficacious, and relapse was greater on placebo than with haloperidol continuation." | 2.76 | A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease. ( Cunqueiro, K; Devanand, DP; Marder, K; Pelton, GH; Sackeim, HA, 2011) |
| "The authors conducted a multicenter, double-blind, placebo-controlled, randomized trial of flexibly dosed quetiapine and haloperidol." | 2.72 | Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. ( Copenhaver, M; Katz, IR; Mintzer, JE; Schneider, L; Street, J; Tariot, PN; Williams-Hughes, C, 2006) |
| "Haloperidol-treated patients showed a worsening on Simpson-Angus scale while there was no significant change in this measure in risperidone-treated patients." | 2.70 | A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. ( Chan, WC; Chiu, HF; Choy, CN; Lam, LC; Leung, VP; Li, SW, 2001) |
| "Carbamazepine has been reported to decrease agitation associated with various psychiatric disorders and to reduce neuroleptic side effects." | 2.68 | Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics. ( Lemke, MR, 1995) |
| " Using an optimizing dosage regime, the outcome variables studied were aggression frequency and the number and nature of emergent side effects." | 2.67 | Aggression in the demented patient: a double-blind study of loxapine versus haloperidol. ( Ancill, RJ; Carlyle, W; Sheldon, L, 1993) |
| "Nineteen patients with probable Alzheimer's disease who manifested psychosis or behavioral disturbance received 0." | 2.67 | Low dose oral haloperidol and blood levels in Alzheimer's disease: a preliminary study. ( Cooper, T; Devanand, DP; Mayeux, R; Sackeim, HA; Taurke, E, 1992) |
| " Renal dosing for topiramate, reduction in PIMs/anticholinergic burden, and substituting haloperidol for olanzapine resolved his violent behavior and CD." | 2.50 | Capgras delusion with violent behavior in Alzheimer dementia: case analysis with literature review. ( Dawood, A; Kaufman, KR; Newman, NB, 2014) |
| "Haloperidol was found to fit readily in Memapsin binding site with IC(50)value 250mM." | 1.42 | Haloperidol inhibits Memapsin 2: innovation by docking simulation and in vitro assay. ( Al-Nadaf, AH; Aldal'in, HK; Taha, MO, 2015) |
| " Our objective was to study the duration of antipsychotic use and factors associated with long-term use (365 days or over) among community-dwelling persons with Alzheimer׳s disease (AD) during a 7-year follow-up." | 1.42 | Long-term use of antipsychotics among community-dwelling persons with Alzheimer׳s disease: A nationwide register-based study. ( Ahonen, R; Hartikainen, S; Koponen, M; Taipale, H; Tanskanen, A; Tiihonen, J; Tolppanen, AM, 2015) |
| "Haloperidol has long been used to manage agitation in dementia, but it is associated with increased side effects." | 1.35 | Multifocal myoclonus induced by haloperidol. ( Benito-León, J; Bermejo-Pareja, F; Domínguez, C, 2009) |
| "Drug-induced delirium is a common matter in the elderly and anticholinergics, together with a number of different drugs, may significantly contribute to the delirium onset, especially in demented people." | 1.34 | Anticholinergic drug-induced delirium in an elderly Alzheimer's dementia patient. ( Cotroneo, A; De Fazio, P; De Fazio, S; De Sarro, G; Gallelli, L; Gareri, P; Lacava, R, 2007) |
| "However, patients with vascular dementia had an increased risk in hospitalization for a CVE." | 1.34 | Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users. ( Barnett, MJ; Perry, PJ; Wehring, H, 2007) |
| "Haloperidol was abruptly shifted to risperidone 0." | 1.31 | Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects. ( Chang, WH; Chang, YC; Chiu, CC; Huang, MC; Lane, HY; Su, MH, 2002) |
| "Unlike the more common causes of dysphagia, especially in the elderly, drug-induced dysphagia may be reversible." | 1.30 | Neuroleptic-induced dysphagia. ( Pavlakovic, R; Sokoloff, LG, 1997) |
| " In this case, NMS seemed to be induced by bacterial pneumonia after long term administration of LPZ 5 mg per day." | 1.30 | [A study of neuroleptic malignant syndrome in the presenium and senium]. ( Honma, H; Koyama, T; Matsubara, S; Suzuki, I; Watanabe, N, 1998) |
| "In the histopathology of Alzheimer's disease (AD) many signs of oxidative reactions can be found building the basis of the oxidative stress hypothesis of AD." | 1.30 | Vitamin E and other antioxidants in neuroprotection. ( Behl, C, 1999) |
| "Two agitated patients with Alzheimer's disease who either failed to respond or worsened with conventional low-dose neuroleptic and other pharmacologic treatment are described." | 1.27 | Very low-dose neuroleptic treatment in two patients with agitation associated with Alzheimer's disease. ( Cubberley, L; Lampe, TH; Risse, SC, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (14.04) | 18.7374 |
| 1990's | 17 (29.82) | 18.2507 |
| 2000's | 24 (42.11) | 29.6817 |
| 2010's | 8 (14.04) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bautista-Aguilera, ÓM | 1 |
| Budni, J | 1 |
| Mina, F | 1 |
| Medeiros, EB | 1 |
| Deuther-Conrad, W | 1 |
| Entrena, JM | 1 |
| Moraleda, I | 1 |
| Iriepa, I | 1 |
| López-Muñoz, F | 1 |
| Marco-Contelles, J | 1 |
| Lalut, J | 1 |
| Santoni, G | 1 |
| Karila, D | 1 |
| Lecoutey, C | 1 |
| Davis, A | 1 |
| Nachon, F | 1 |
| Silman, I | 1 |
| Sussman, J | 1 |
| Weik, M | 1 |
| Maurice, T | 1 |
| Dallemagne, P | 1 |
| Rochais, C | 1 |
| Kumar, S | 2 |
| Chowdhury, S | 1 |
| Kaufman, KR | 1 |
| Newman, NB | 1 |
| Dawood, A | 1 |
| Al-Nadaf, AH | 1 |
| Taha, MO | 1 |
| Aldal'in, HK | 1 |
| Shimizu, S | 1 |
| Mizuguchi, Y | 1 |
| Sobue, A | 1 |
| Fujiwara, M | 1 |
| Morimoto, T | 1 |
| Ohno, Y | 1 |
| Koponen, M | 1 |
| Taipale, H | 1 |
| Tanskanen, A | 1 |
| Tolppanen, AM | 1 |
| Tiihonen, J | 1 |
| Ahonen, R | 1 |
| Hartikainen, S | 1 |
| Domínguez, C | 1 |
| Benito-León, J | 1 |
| Bermejo-Pareja, F | 1 |
| Devanand, DP | 4 |
| Pelton, GH | 2 |
| Cunqueiro, K | 1 |
| Sackeim, HA | 4 |
| Marder, K | 2 |
| Onalaja, D | 1 |
| Jainer, AK | 1 |
| Rosenthal, M | 1 |
| Berkman, P | 1 |
| Shapira, A | 1 |
| Gil, I | 1 |
| Abramovitz, J | 1 |
| Nagura, H | 1 |
| Warner, J | 1 |
| Butler, R | 1 |
| Arya, P | 1 |
| Cummings, JL | 1 |
| Tractenberg, RE | 3 |
| Gamst, A | 2 |
| Teri, L | 3 |
| Masterman, D | 1 |
| Thal, LJ | 3 |
| Verhey, FR | 1 |
| Verkaaik, M | 1 |
| Lousberg, R | 1 |
| Suh, GH | 1 |
| Shah, A | 1 |
| Savaskan, E | 1 |
| Schnitzler, C | 1 |
| Schröder, C | 1 |
| Cajochen, C | 1 |
| Müller-Spahn, F | 1 |
| Wirz-Justice, A | 1 |
| Tariot, PN | 1 |
| Schneider, L | 1 |
| Katz, IR | 1 |
| Mintzer, JE | 1 |
| Street, J | 1 |
| Copenhaver, M | 1 |
| Williams-Hughes, C | 1 |
| Gareri, P | 1 |
| De Fazio, P | 1 |
| Cotroneo, A | 1 |
| Lacava, R | 1 |
| Gallelli, L | 1 |
| De Fazio, S | 1 |
| De Sarro, G | 1 |
| Wang, S | 1 |
| Zhu, L | 1 |
| Shi, H | 1 |
| Zheng, H | 1 |
| Tian, Q | 1 |
| Wang, Q | 1 |
| Liu, R | 1 |
| Wang, JZ | 1 |
| Harrison, BE | 1 |
| Therrien, B | 1 |
| Barnett, MJ | 1 |
| Wehring, H | 1 |
| Perry, PJ | 2 |
| Lemke, MR | 1 |
| Carlyle, W | 1 |
| Ancill, RJ | 1 |
| Sheldon, L | 1 |
| Sunderland, T | 1 |
| Higaki, J | 1 |
| Murphy, GM | 1 |
| Cordell, B | 1 |
| Regan, WM | 1 |
| Gordon, SM | 1 |
| Auer, SR | 1 |
| Monteiro, IM | 1 |
| Reisberg, B | 1 |
| Sokoloff, LG | 1 |
| Pavlakovic, R | 1 |
| Auchus, AP | 2 |
| Bissey-Black, C | 1 |
| Caligiuri, MP | 1 |
| Rockwell, E | 1 |
| Jeste, DV | 1 |
| Suzuki, I | 1 |
| Honma, H | 1 |
| Watanabe, N | 1 |
| Matsubara, S | 1 |
| Koyama, T | 1 |
| Michaels, KS | 1 |
| Bell, K | 1 |
| Sullivan, MA | 1 |
| Cooper, TB | 1 |
| Mayeux, R | 3 |
| Behl, C | 1 |
| Frisoni, GB | 1 |
| Bianchetti, A | 1 |
| Pignatti, F | 1 |
| Gozzetti, A | 1 |
| Trabucchi, M | 1 |
| De Deyn, PP | 1 |
| Logsdon, RG | 1 |
| Peskind, E | 1 |
| Raskind, M | 1 |
| Weiner, MF | 2 |
| Foster, NL | 1 |
| Schneider, LS | 1 |
| Sano, M | 2 |
| Whitehouse, P | 1 |
| Tariot, P | 1 |
| Mellow, AM | 1 |
| Grundman, M | 1 |
| Thomas, RG | 1 |
| Schafer, K | 1 |
| Andorn, AC | 1 |
| Pappolla, MA | 1 |
| Hatch, CD | 1 |
| Lund, BC | 1 |
| Chan, WC | 1 |
| Lam, LC | 1 |
| Choy, CN | 1 |
| Leung, VP | 1 |
| Li, SW | 1 |
| Chiu, HF | 1 |
| Lane, HY | 1 |
| Chang, YC | 1 |
| Su, MH | 1 |
| Chiu, CC | 1 |
| Huang, MC | 1 |
| Chang, WH | 1 |
| Sultzer, DL | 1 |
| Gray, KF | 1 |
| Gunay, I | 1 |
| Wheatley, MV | 1 |
| Mahler, ME | 1 |
| González Moneo, MJ | 1 |
| Garrido Barral, A | 1 |
| Logsdon, R | 1 |
| Galasko, D | 1 |
| Thomas, R | 1 |
| Cooper, T | 2 |
| Taurke, E | 1 |
| Aisen, PS | 1 |
| Lawlor, BA | 1 |
| Tune, LE | 1 |
| Steele, C | 2 |
| Coccaro, EF | 1 |
| Kramer, E | 1 |
| Zemishlany, Z | 1 |
| Thorne, A | 1 |
| Rice, CM | 1 |
| Giordani, B | 1 |
| Duvvi, K | 1 |
| Patel, BM | 1 |
| Torres, J | 1 |
| Nora, R | 1 |
| Brown, RP | 1 |
| Jensen, CF | 1 |
| Risse, SC | 1 |
| Lampe, TH | 1 |
| Cubberley, L | 1 |
| Davidson, M | 1 |
| Powchik, P | 1 |
| Davis, KL | 1 |
| Lucas, MJ | 1 |
| Tune, L | 1 |
| Rosse, RB | 1 |
| Allen, A | 1 |
| Lux, WE | 1 |
| Serby, M | 1 |
| Ostergaard, PK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Behavioral Symptoms in Alzheimer's Disease[NCT00009217] | Phase 4 | 44 participants (Actual) | Interventional | 1999-01-31 | Completed | ||
| Treatment of Psychosis and Agitation in Alzheimer's Disease[NCT02129348] | Phase 2 | 77 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| [NCT00000179] | Phase 3 | 0 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Basic Activities of Daily Living with items for 6 functions: bathing, dressing, toileting, transferring, continence, and feeding. Each item is scored as unimpaired=1, impaired=0. Total score is the measure used, range 0-6; higher scores indicate better functioning. (NCT02129348)
Timeframe: Assessed at Week 0, Week2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.3 |
| Placebo Group | 0.1 |
Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain is the measure used that combines symptoms of agitation and aggression. Frequency X Severity rating score, range 0-12. Higher score indicates more agitation and aggressive behavior. (NCT02129348)
Timeframe: Assessed at screening, Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 3.2 |
| Placebo Group | 2.5 |
Clinical Global Impression (CGI) Behavior Change score is the measure used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Scores ranging from 1-3 indicate improvement. Only patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Lithium Treatment Group | 12 |
| Placebo Group | 8 |
The patient is classified as a responder (score=1) if both criteria are met or as a non-responder (score=0) if both criteria are not met. The first criterion to determine responder status, NPI core score, has a scoring range 0-36; each of the three component scores for symptoms of agitation/aggression, delusions and hallucinations has a scoring range 0-12. For each symptom and the total score, higher score indicates more symptoms. The second criterion to determine responder status, Clinical Global Impression (CGI), is used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Only patients who met both criteria, assessed as change compared to baseline, were counted as responders; all other patients were non-responders. Patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Lithium Treatment Group | 12 |
| Placebo Group | 7 |
30 item questionnaire used to assess degree of cognitive impairment. Orientation, registration, attention/calculation, recall, language, repetitions and commands are assessed. Total score is the measure used; range 0-30, higher scores indicate better global cognitive function. (NCT02129348)
Timeframe: Assessed at Screening, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.9 |
| Placebo Group | 0.9 |
Neuropsychological test used to assess a patient's cognitive ability. The patient is asked to complete small tasks such as drawing shapes and printing their name. They are also asked to remember certain names and objects, such as a cup and a spoon, and the evaluator's first name. Total score is the measure used; range 0-100, higher scores indicate better cognition. (NCT02129348)
Timeframe: Assessed at Week 0, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 2.1 |
| Placebo Group | -0.0 |
Simpson Angus Scale for Extrapyramidal Sign requires in-person examination to assess gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella tap, tremor, and salivation. Total score is the measure used, range 0-40; higher scores indicate increased severity of signs. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | -0.0 |
| Placebo Group | 0.0 |
Treatment Emergent Symptom Scale that covers 26 somatic symptoms, each rated as present (score=1) or absent (score=0). Total score is the measure used with scoring range 0-26; higher scores indicate more somatic symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.6 |
| Placebo Group | 0.7 |
Young Mania Rating Scale total score is the measure used to assess symptoms that occur in mania; each item is a symptom that is rated for severity. Scoring range 0-60; higher scores indicate more severe symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 3.1 |
| Placebo Group | 1.1 |
Zarit Caregiver Burden Interview with the caregiver asked to rank 22 items on a scale with responses for each item from 'never' (score 0) to 'nearly always' (score 4). Total score is the measure used; range 0-88 with higher scores indicating greater caregiver burden. (NCT02129348)
Timeframe: Assessed at Week 0, Week 4, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 2.8 |
| Placebo Group | -0.4 |
5 reviews available for haloperidol and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Capgras delusion with violent behavior in Alzheimer dementia: case analysis with literature review.
Topics: Aged; Aggression; Alzheimer Disease; Amitriptyline; Anticonvulsants; Antidepressive Agents, Tricycli | 2014 |
[Drugs for the treatment of Alzheimer's disease].
Topics: Acetylcholine; Alzheimer Disease; Antidepressive Agents; Cerebral Cortex; Cholinesterase Inhibitors; | 2004 |
Dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cognition; Dementia; Donepezil; Galantamin | 2004 |
Treatment of the elderly suffering from psychosis and dementia.
Topics: Age Factors; Aged; Alzheimer Disease; Antipsychotic Agents; Buspirone; Clinical Trials as Topic; Dem | 1996 |
[Latest therapies for treating dementia].
Topics: Adult; Aged; Alzheimer Disease; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepress | 2002 |
19 trials available for haloperidol and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; Female; Halop | 2011 |
Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Hal | 2006 |
Treatment of behavioural, cognitive and circadian rest-activity cycle disturbances in Alzheimer's disease: haloperidol vs. quetiapine.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Antips | 2006 |
Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Bri | 2006 |
Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamazepine; Drug Therapy, Combination; Female; Follow | 1995 |
Aggression in the demented patient: a double-blind study of loxapine versus haloperidol.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Basal Ganglia Diseases; Dementia; Dementia, | 1993 |
Behavioral symptoms in dementia: community-based research.
Topics: Aged; Alzheimer Disease; Ambulatory Care; Antipsychotic Agents; Dementia; Double-Blind Method; Femal | 1996 |
Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Double-Blin | 1997 |
A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.
Topics: Aged; Aggression; Alzheimer Disease; Ambulatory Care; Basal Ganglia Diseases; Brief Psychiatric Rati | 1998 |
Haloperidol an Alzheimer's disease.
Topics: Alzheimer Disease; Ambulatory Care; Behavioral Symptoms; Haloperidol; Hospitalization; Humans; Italy | 1999 |
Treatment of agitation in AD: a randomized, placebo-controlled clinical trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavior Therapy; Double-Blind Method; Female; Haloperid | 2000 |
A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia, Vascular; Double-Blind Method; Female; Haloper | 2001 |
Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia?
Topics: Aged; Alzheimer Disease; Analysis of Variance; Antidepressive Agents, Second-Generation; Antipsychot | 2001 |
No long-term effect of behavioral treatment on psychotropic drug use for agitation in Alzheimer's disease patients.
Topics: Aged; Alzheimer Disease; Anti-Anxiety Agents; Antipsychotic Agents; Behavior Therapy; Caregivers; Fe | 2002 |
Low dose oral haloperidol and blood levels in Alzheimer's disease: a preliminary study.
Topics: Aged; Alzheimer Disease; Double-Blind Method; Female; Haloperidol; Humans; Male; Psychiatric Status | 1992 |
Neuroleptic drugs in the management of behavioral symptoms of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Behavior; Double-Blind Method; Female; Haloperidol; H | 1991 |
Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Diphenhydramine; D | 1990 |
A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Clinical Trials as Topic; Double-Blind Method; | 1989 |
Haloperidol versus thioridazine in the treatment of behavioral symptoms in senile dementia of the Alzheimer's type: preliminary findings.
Topics: Aged; Alzheimer Disease; Basal Ganglia Diseases; Drug Evaluation; Fatigue; Female; Haloperidol; Huma | 1986 |
33 other studies available for haloperidol and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Contilisant, a Tetratarget Small Molecule for Alzheimer's Disease Therapy Combining Cholinesterase, Monoamine Oxidase Inhibition, and H3R Antagonism with S1R Agonism Profile.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterases; Histamine Antagonists; Indoles; | 2018 |
Novel multitarget-directed ligands targeting acetylcholinesterase and σ
Topics: Acetylcholinesterase; Alzheimer Disease; Aniline Compounds; Animals; Cholinesterase Inhibitors; Crys | 2019 |
In silico repurposing of antipsychotic drugs for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid Precursor Protein Secretases; Antipsychotic Agents; | 2017 |
Haloperidol inhibits Memapsin 2: innovation by docking simulation and in vitro assay.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Aspartic Acid Endopeptidases; Binding Sites | 2015 |
Interaction between anti-Alzheimer and antipsychotic drugs in modulating extrapyramidal motor disorders in mice.
Topics: Alzheimer Disease; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Cholinesterase Inhibitors; | 2015 |
Long-term use of antipsychotics among community-dwelling persons with Alzheimer׳s disease: A nationwide register-based study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cohort Studies; Female; Finland; F | 2015 |
Multifocal myoclonus induced by haloperidol.
Topics: Alzheimer Disease; Antipsychotic Agents; Female; Haloperidol; Humans; Middle Aged; Myoclonus | 2009 |
Risperidone and dementia-related aggression: new indication. A last resort, no better than haloperidol.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Dementia; Drug Approval; Europe; France; | 2009 |
Re: Chan et al. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 16: 1156 - 1162.
Topics: Alzheimer Disease; Antipsychotic Agents; China; Double-Blind Method; Haloperidol; Humans; Mental Dis | 2002 |
Urethral masturbation and sexual disinhibition in dementia: a case report.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Foreign Bodies; Haloperidol; Human | 2003 |
Regression to the mean: implications for clinical trials of psychotropic agents in dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Behavior Therapy; Data Interpretat | 2004 |
Effect of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Confidence Intervals; Dementia, Va | 2005 |
Anticholinergic drug-induced delirium in an elderly Alzheimer's dementia patient.
Topics: Acute Disease; Aged, 80 and over; Alzheimer Disease; Amitriptyline; Antipsychotic Agents; Cholinergi | 2007 |
Inhibition of melatonin biosynthesis induces neurofilament hyperphosphorylation with activation of cyclin-dependent kinase 5.
Topics: Alzheimer Disease; Animals; Cerebral Cortex; Cyclin-Dependent Kinase 5; Dopamine Antagonists; Enzyme | 2007 |
Effect of antipsychotic medication use on memory in patients with Alzheimer's disease: Assessing the potential risk for accelerated recent autobiographical memory loss.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Autobiographies as Topic; Benzodiazepines; Dibenzothi | 2007 |
Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Databases, Factual; Dementia, Vascul | 2007 |
Inhibition of beta-amyloid formation by haloperidol: a possible mechanism for reduced frequency of Alzheimer's disease pathology in schizophrenia.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antipsychotic Agents; CHO Cells; Cricetinae; Dose | 1997 |
Gabapentin for behavioral agitation in Alzheimer's disease.
Topics: Acetates; Aged; Alzheimer Disease; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Admini | 1997 |
Neuroleptic-induced dysphagia.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Deglutition Disorders; Fluoroscopy; Haloperidol; Huma | 1997 |
Extrapyramidal side effects in patients with Alzheimer's disease treated with low-dose neuroleptic medication.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Antipsychotic Agents; Basal Gangli | 1998 |
[A study of neuroleptic malignant syndrome in the presenium and senium].
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Female; Haloperidol; Humans; Male | 1998 |
Vitamin E and other antioxidants in neuroprotection.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipsychotic Agents; Estrogens; Female; Fre | 1999 |
Treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Haloperidol; Humans; Risperidone | 2000 |
Catecholamines inhibit lipid peroxidation in young, aged, and Alzheimer's disease brain.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adult; Aged; Aging; Alzheimer Disease; Autopsy; Brain; Catec | 2001 |
Failed challenge with quetiapine after neuroleptic malignant syndrome with conventional antipsychotics.
Topics: Alzheimer Disease; Antipsychotic Agents; Chlorpromazine; Dibenzothiazepines; Haloperidol; Humans; Hy | 2001 |
Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects.
Topics: Activities of Daily Living; Affect; Aged; Alzheimer Disease; Antipsychotic Agents; Dementia, Vascula | 2002 |
Neuroleptic malignant syndrome induced by low-dose haloperidol.
Topics: Alzheimer Disease; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Injections, Intram | 1992 |
Hypersexual agitation in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Haloperidol; Humans; Hydroxyzine; Male; Pindolol; Sex Offenses; Sexual Beha | 1989 |
Very low-dose neuroleptic treatment in two patients with agitation associated with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Haloperidol; Humans; Male; Middle | 1987 |
Pisa syndrome in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Amantadine; Drug Therapy, Combination; Dystonia; Haloperidol; Humans; Male; | 1988 |
Baclofen treatment in a patient with tardive dystonia.
Topics: Aged; Alzheimer Disease; Baclofen; Dystonia; Female; Haloperidol; Humans | 1986 |
Neuroleptic malignant syndrome in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; Risk | 1986 |
Capgras syndrome in senile dementia of the Alzheimer type.
Topics: Aged; Alzheimer Disease; Capgras Syndrome; Clomipramine; Female; Haloperidol; Humans; Psychotic Diso | 1985 |